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A B S T R A C T
Metabolites, the small molecules that underpin life, can act as indicators of the physiological state of the body
when their abundance varies, oﬀering routes to diagnosis of many diseases. The ability to assay for multiple
metabolites simultaneously will underpin a new generation of precision diagnostic tools. Here, we report the
development of a handheld device based on complementary metal oxide semiconductor (CMOS) technology with
multiple isolated micro-well reaction zones and integrated optical sensing allowing simultaneous enzyme-based
assays of multiple metabolites (choline, xanthine, sarcosine and cholesterol) associated with multiple diseases.
These metabolites were measured in clinically relevant concentration range with minimum concentrations
measured: 25 μM for choline, 100 μM for xanthine, 1.25 μM for sarcosine and 50 μM for cholesterol. Linking the
device to an Android-based user interface allows for quantiﬁcation of metabolites in serum and urine within
2min of applying samples to the device. The quantitative performance of the device was validated by com-
parison to accredited tests for cholesterol and glucose.
1. Introduction
Many diseases are accompanied by perturbations to normal levels of
the small molecules collectively called “metabolites” within bioﬂuids.
As our ability to identify and quantify multiple small molecules has
improved in recent years, it has become clear that many diseases are
characterised by diﬀerences in metabolite levels (Asiago et al., 2010;
Griﬃn et al., 2011; Griﬃn and Shockcor, 2004; Guo et al., 2015;
Mazzu-Nascimento et al., 2016; Mendrick and Schnackenberg, 2009;
Nicholson et al., 2012; Sreekumar et al., 2009; Sullivan et al., 2016; Sun
et al., 2013). Metabolomics technologies that aim to measure all small
molecules in a given system have been at the centre of this increased
appreciation of metabolite biomarkers of disease. Metabolomics usually
involves one of two platforms to proﬁle metabolites: nuclear magnetic
resonance (NMR) and mass spectrometry coupled to liquid or gas
chromatographic separation systems e.g. (LC/GC-MS). NMR based
measurements are highly quantitative, but suﬀer from a relative lack of
sensitivity, with only the most abundant molecules visible (Malet-
Martino and Martino, 1991). Hyphenated mass spectrometry based
approaches are far more sensitive and cover a greater range of meta-
bolites, but lack the ability to quantify metabolites without additional
steps in the analytical process (Fernie et al., 2004). In both cases the
basic instrumentation is expensive and not suitable for point-of-care
(POC) analysis. New methodologies are required if metabolomics is to
be democratised, hence novel ways of measuring multiple metabolites
simultaneously are required. Complementary metal oxide semi-
conductor (CMOS) technology, the mainstay of low-cost electronics, has
proven to be of great utility in allowing coupling of many biological
processes to electronic measurement (Abbott et al., 2017; Bellin et al.,
2016; Piliarik and Sandoghdar, 2014). Exploiting CMOS technology to
provide new scalable metabolite measurement platforms also shows
excellent potential. An approach to metabolite measurement that can
be applied to CMOS technology involves enzymes capable of re-
cognising particular metabolites. Enzymes have exquisite sensitivity for
their metabolite substrates that can be quantiﬁed based on the rate at
which they are reacted upon by enzymes. Because of the ultra-high
packing density of CMOS based sensors, this technology has the capa-
city to interrogate a large number of biochemical reactions provided
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T
surface engineering can keep reactions discrete. Enzyme reactions can
be followed using detection systems capable of integration into a CMOS
circuit enabling selective measurement of metabolites in bodily ﬂuids
placed on a chip's surface. Both individual as well as simultaneous
measurement of glucose and cholesterol have been demonstrated on a
semiconductor platform (Al-Rawhani et al., 2017; Cheah et al., 2016;
Hu et al., 2017). Similarly, immunoassays have also been demonstrated
(Nagy et al., 2018). In principle, a multitude of enzymes, each
speciﬁc for a given metabolite, could be multiplexed onto the same
CMOS-chip surface, scaling to a point where as many metabolites
for which enzymes are available could potentially be measured si-
multaneously.
The ability to detect and quantify multiple metabolite biomarkers
simultaneously and rapidly can be of the utmost importance for the
critical disease conditions such as acute myocardial infarction and
acute ischaemic stroke. Immediate application of the most appropriate
therapeutic management can greatly improve outcomes in these dis-
eases (Neumann et al., 2016; Rothwell et al., 2007). In many cancers
too, it is becoming clear that therapeutic choices based on metabolite
proﬁles oﬀer improved outcomes (Puchades-Carrasco and Pineda-
Lucena, 2017). In this article, we present a handheld device for the
simultaneous rapid detection and quantiﬁcation of a representative
panel of multiple metabolites: choline (Adamczyk et al., 2006; Danne
et al., 2003; Danne and Möckel, 2010; Wang et al., 2011); xanthine
(Chouchani et al., 2014; Dawson and Walters, 2006; Farthing et al.,
2015; Harmsen et al., 1981); sarcosine (Cernei et al., 2013; Mazzu-
Nascimento et al., 2016; Sreekumar et al., 2009; Wang et al., 2017); and
cholesterol (Holmes et al., 2017). Each of these metabolites has been
implicated in one or more critical disease states such as acute ischaemia
(for heart or brain), acute renal failure and prostate cancer, thus de-
monstrate the feasibility and purpose of simultaneously quantifying
multiple metabolites on a single chip (Danne and Möckel, 2010;
Farthing et al., 2015; Holmes et al., 2017; Li et al., 2015; Sreekumar
et al., 2009). Metabolite-speciﬁc enzyme assays used with an array of
sensors based on CMOS technology has enabled this multiplexed me-
tabolite measurement. The CMOS-chip surface consists of a 16×16
pixel array divided into four discrete micro-wells, one for each speciﬁc
metabolite, thus enabling rapid simultaneous detection of multiple
metabolites. This simple device is operable using any Android based
tablet or smartphone that provides data acquisition, computation, vi-
sualisation and power through a USB connector.
2. Materials and methods
2.1. CMOS-chip design
A 3.4 mm×3.6mm chip was designed and fabricated using an
Austria microsystems (AMS) 350 nm triple-well process. This chip has
16×16 array of sensor pixels with an active area of 1.6mm×1.6mm
and was designed using Cadence Virtuoso software package.
2.2. Fabrication of micro-wells
The active area surface of a CMOS-chip, with pixel array for the
sensors, was protected by four polydimethylsiloxane (PDMS) micro-
blocks of 600 µm×600 µm and height of 1500 µm (SYLGARD 184
Silicone Elastomer Kit, Dow Corning). These PDMS blocks serve two
purposes: (1) they act as a sacriﬁcial material helping shape the micro-
casting of black epoxy (EPO-TEC 302–3M Black Kit, Epoxy Technology
Inc.) to fabricate the micro-wells, and (2) they also protect the active
pixel array area of CMOS-chip against damage from epoxy or from
physical damage through scratches. Cast PDMS used in this process was
never older than 14 h. These PDMS blocks were carefully placed on top
of the active pixel array using the assistive translation stage of a ﬂip-
chip bonder (Semiconductor Equipment Corporation, Model 850). The
epoxy mixture was carefully decanted over the CMOS-chip surface
around the PDMS blocks and over the contact pads. Overnight curing at
a maximum temperature of 60 °C caused the epoxy resin to harden. A
clear plastic ring of approximately 8mm height was placed around the
CMOS-chip on a ceramic chip carrier to form a reaction cell. Four
quadrant separation walls were made using selective micro-cavity
casting of black epoxy (Fig. S1, Supplementary Information). These
micro-wells have pipettable access. This unique design does not require
micro-tubing or pumps to handle the liquid, avoiding complex liquid
handling. The method also allows instantaneous mixing of reagents
with micro-wells, reducing the assay time by avoiding ﬂuid travel de-
lays that micro-tubing would introduce.
2.3. On-chip metabolite assays
The assay reagents and the commercially available enzymes used were
from Sigma-Aldrich Company Ltd. (Dorset, UK). The enzymes, choline
oxidase (CHOD) from Alcaligenes sp., xanthine oxidase (XOD) from
Escherichia coli K-12, sarcosine oxidase (SOX) from Bacillus sp., cholesterol
esterase from Pseudomonas sp., cholesterol oxidase (COD) from
Streptomyces sp., glucose oxidase (GOD) from Aspergillus niger, and horse-
radish peroxidase (HRP) from Amoracia rusticana roots, were all obtained
as lyophilised powders, which were reconstituted in their respective assay
buﬀers before on-chip assays. The sterile-ﬁltered serum sample used was
from human male AB plasma (Sigma-Aldrich) and the urine sample used
was obtained from a local volunteer. An assay mixture of 500 µl was used
for on-chip assays to eﬀectively cover the active chip sensor array as well as
the surrounding surface within the chip-enclosure ring.
2.3.1. Choline
An enzymatic assay based on CHOD was employed to measure
choline (Hiroaki et al., 1977; Keesey, 1987). The assays were performed
in 100mM Tris-HCl buﬀer (pH 8.0) and diluted serum using 2.5 units
(U) of CHOD, where choline was oxidised to betaine with the si-
multaneous production of hydrogen peroxide (H2O2). The formed H2O2
was measured on a CMOS-Photodiode (PD) sensor array (Fig. 2d) using
a phenol/4-aminoantipyrine/HRP coupled reaction system to produce
quinoneimine dye (λmax at 553 nm) (Rautela and Liedtke, 1978).
Choline concentration in the assays was varied from 25 μM to 500 µM.
2.3.2. Xanthine
An enzymatic assay based on XOD was employed to measure xan-
thine (Roussos, 1967). The assays were performed in 50mM trietha-
nolamine buﬀer (pH 7.5) and diluted serum using 2.0 U of XOD, where
xanthine was oxidised to uric acid with the simultaneous production of
H2O2. The formed H2O2 was measured on a CMOS-PD sensor array
using a phenol/4-aminoantipyrine/HRP coupled reaction system to
produce quinoneimine dye (Rautela and Liedtke, 1978). Xanthine
concentration in the assays was varied from 100 µM to 1.6 mM.
2.3.3. Sarcosine
An enzymatic assay based on SOX was employed to measure sar-
cosine (Suzuki, 1981). Sarcosine assays were performed in 60mM
glycylglycine buﬀer (pH 8.3) and diluted urine using 4.1 U of SOX,
where sarcosine was oxidised to glycine and formaldehyde with the
simultaneous production of H2O2. The formed H2O2 was measured on a
CMOS-PD sensor array using an o-dianisidine/HRP coupled reaction
system to produce oxidised o-dianisidine (λmax at 540 nm) (Porstmann
et al., 1981). Sarcosine concentration in the assays was varied from
1.25 μM to 10mM.
2.3.4. Cholesterol
An enzymatic assay based on COD was employed to measure
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cholesterol (Amundson and Zhou, 1999). Cholesterol assays were per-
formed in 50mM triethanolamine buﬀer (pH 7.5) and diluted serum
with 1.2 U of COD, where cholesterol esterase-treated (~30min at
37 °C) cholesterol was oxidised to a ketone product (5-cholesten-3-one)
with the simultaneous production of H2O2. The formed H2O2 was
measured on a CMOS-PD sensor array using an o-dianisidine/HRP
coupled reaction system to produce oxidised o-dianisidine. Cholesterol
concentration in the assays was varied from 50 μM to 870 μM.
2.3.5. Glucose
An enzymatic assay based on GOD was employed to measure glu-
cose (Washko and Rice, 1961). Glucose assays were performed in
50mM triethanolamine buﬀer (pH 7.5) and diluted serum with 1.2 U of
GOD, where glucose was oxidised to a lactone (D-glucono-1,5-lactone)
with the simultaneous production of H2O2. The formed H2O2 was
measured on a CMOS-PD sensor array using an o-dianisidine/HRP
coupled reaction system to produce oxidised o-dianisidine. Glucose
concentration in the assay was varied from 700 µM to 5.6mM.
2.3.6. Calculation of the rates
The rates were estimated from the slope of the tangent drawn to the
portion of the curve representing the initial rate (Purich, 2010). For the
determination of the calibration curves, the background rates due to the
presence of endogenous serum metabolites were subtracted from the
rates obtained for the serum samples to which known quantities of
metabolite were added.
2.4. Android-based data acquisition application
An Android data acquisition Application was developed for the
multiplexed sensing. The App displays the data acquired from the
sensor array in three diﬀerent formats: a greyscale image; 4 time do-
main graphs of selected pixels; and a bar chart showing current signal
levels of the selected pixels. The application triggers the platform to
send a data frame at the rate of 10 frames per second, which can be
adjusted in the source code. The acquired data can be stored into a .CSV
ﬁle for later analysis.
Fig. 1. A handheld prototype for the multiplexed assaying of metabolites. (a) Prototype consisting of a post-processed CMOS-chip with electronic readout
attached to an Android-based tablet for data acquisition. (b) The handheld device with CMOS-chip. (c) Top-view of a ﬂuid retaining ring bonded on to the ceramic
chip carrier with the micro-well structure at the centre. (d) Side-view of the packaged structure. (e) A more detailed top-view of the micro-well structure over the
chip. (f) Side-view, showing isolated reaction zones for assaying of four diﬀerent metabolites with speciﬁc enzymes in individual micro-wells.
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3. Results and discussion
3.1. A handheld multi-metabolite measuring CMOS-based platform
A CMOS based hand held device developed for the simultaneous,
rapid detection and quantiﬁcation of multiple metabolite biomarkers is
presented (Figs. 1a and 1b). Metabolites were detected using assays
within discrete micro-wells; one for each metabolite (Fig. 1c-f) whose
concentrations in blood or urine vary with diﬀering types of diseases.
The device demonstrates the potential to create a new miniaturised
approach to metabolomic analysis. The CMOS 16×16 pixel array is
shown in Figs. 2a and 2b. Each pixel consists of a photodiode (Figs. 2b
and 2c). The chip was designed and fabricated using an Austria mi-
crosystems (AMS) 350 nm triple-well process that allowed the sensors
to be isolated from each other to achieve minimum cross talk. The
photodiode has a measured peak responsivity of 21.6 mV/µW at a
wavelength of 600 nm (Fig. S2, Supplementary Information). The sur-
face of the CMOS-chip was post-processed and partitioned to create
micro-wells on the chip surface. These micro-wells were fabricated
using additive epoxy micro-casting using PDMS as a sacriﬁcial layer
(see Section 2.2). Figs. 1c and 1d provide a schematic view for the post-
processed packaged CMOS-chip with micro-wells in the centre of the
package. These micro-wells form isolated reaction zones, each for an
individual metabolite biomarker (Figs. 1e and 1f) using enzyme-based
assays to detect four diﬀerent metabolites.
Enzymes that produce H2O2 can be coupled to reactions oﬀering an
assay that exhibits a colour change; in this work we achieve this
through coupling to HRP. Such a coupled colorimetric assay can be
monitored in real time using a photodiode. As illustrated in Fig. 2d the
photodiode array integrated in a CMOS platform can, therefore, be used
for the quantiﬁcation of metabolites based on the incident light in-
tensity after transmission through the respective assay solutions. After
fabrication, each micro-well has an array of approximately 5×5 pixels
with photodiodes to sense the reaction and to provide a statistically
averaged output signal over the micro-well area as shown in Fig. 2e. A
typical output signal from individual photodiode pixels across the en-
tire CMOS-chip is shown in Fig. 2f. The spatial surface plot for the
signal exhibits the distinct reaction zones of each micro-well and assay.
A standard deviation of output signal for a CMOS-chip with diﬀerent
numbers of reaction wells was evaluated (Fig. S3, Supplementary
Information).
Fig. 2. CMOS-chip architecture. (a) CMOS-
chip with a 16×16 array of sensor pixels. (b)
Magniﬁed view of a CMOS-chip with a dashed
square showing a single sensor pixel. (c) An
optical proﬁlometry micrograph of a single
CMOS-chip sensor pixel showing a photodiode.
(d) Schematic depiction of the sensing prin-
ciple employed for metabolite sensing in four
micro-wells using light-emitting diodes (LED)
and photodiode (PD) sensors. (e) Schematic of
a CMOS-chip circuit showing the division of a
16×16 pixel array into four micro-wells. The
micro-well boundaries are shown by dashed
lines. (f) Photodiode signal from the four
micro-wells, shown as a surface plot, acquired
during simultaneously assays for four metabo-
lites.
S.B. Patil et al. Biosensors and Bioelectronics 122 (2018) 88–94
91
3.2. Identiﬁcation of individual and multiple metabolites
Measurements were carried out on metabolites dissolved in various
solvents including buﬀer, serum and urine using enzymes speciﬁc for a
range of metabolites. Assays for these metabolites were optimised,
standardised and quantiﬁed on the CMOS-chip surface either one at a
time or in pairs across the micro-wells to record statistical variation.
The choline level in serum is emerging as a biomarker to detect
early onset of troponin-positive cardiac ischaemia (Danne et al., 2003;
Danne and Möckel, 2010; Wang et al., 2011), where levels of 20–60 µM
are reported in comparison to concentrations in a healthy individuals of
around 10 μM (Adamczyk et al., 2006; Danne et al., 2003; Danne and
Möckel, 2010). We employed a colorimetric coupled assay based on
CHOD generated H2O2 for detection and quantiﬁcation of choline. To
assess the linear dynamic range for choline on the CMOS platform, we
measured choline in buﬀer and also in the presence of diluted serum
over a concentration range of 25–500 µM (Fig. 3a-b). We were able to
reliably detect the lowest choline concentration of 25 µM which would
be detectable in diseased but not healthy individuals.
Xanthine oxidase and its speciﬁc metabolite substrates, xanthine
and hypoxanthine, have also been recognised as biomarkers for
ischaemia (Ali et al., 2013; Chouchani et al., 2014; Farthing et al.,
2015), as well as for other diseases including acute renal failure
(Bradbury et al., 1995). Here, we used a colorimetric coupled assay
based on XOD generated H2O2 for the detection and quantiﬁcation of
xanthine, both in buﬀer (Fig. 3c) and in diluted serum (Fig. 3d) over a
concentration range from 100 µM to 1.6 mM.
Sarcosine, a non-proteinogenic amino acid metabolite, has normal
levels of around 0.02 µM in urine samples of healthy individuals.
Elevated levels of sarcosine were observed in urine during progression
and metastasis of prostate cancer and can reach elevated levels of
~5 μM (Cernei et al., 2013). We successfully measured sarcosine, using
a colorimetric coupled assay based on SOX generated H2O2, in buﬀer
over a concentration range of 1.25 μM to 10mM (Fig. 3e) and also in
diluted urine (Fig. 3f) down to a concentration of 5 μM.
3.3. On-chip enzyme kinetics and validation of CMOS device
Validation of the on-chip assays for the 4-assay system was carried
out using similar protocols to those used in single assay chips (Al-
Rawhani et al., 2017; Hu et al., 2017). Details of the work done using
the present 4-assay system are provided in the Supplementary
Information (Section 4, Fig. S4).
Measurements were carried out to obtain on-chip kinetics in buﬀer
and diluted serum, for choline, xanthine, sarcosine, and cholesterol.
Fig. 3g-h and Figs. S4a-b (see Supplementary Information) show that
there was a metabolite concentration-dependent change in the sensor
response. Control reactions showed no response or showed a response
equivalent to the endogenous metabolite concentration in the diluted
serum (shaded part of the curves in the Fig. 3g-h and Figs. S4a-b). In
Fig. 3. Response of photodiode sensor array from four micro-wells for simultaneous detection of four diﬀerent metabolites. (a) Photodiode response for the
detection of choline in buﬀer with concentrations varied from 25 μM to 500 µM. (b) Photodiode response for the detection of choline in diluted serum, with
concentrations varied from 25 μM to 500 μM. (c) Photodiode signal response for the detection of xanthine in buﬀer with concentrations varied from 100 μM to
1.6mM. (d) Photodiode signal response for the detection of xanthine in diluted serum, with the concentrations varied from 0.1mM to 0.8 mM. (e) Photodiode signal
response for the detection of sarcosine in buﬀer with concentrations varied from 1.25 μM to 10mM. (f) Photodiode signal response for the detection of sarcosine in
diluted urine, with concentrations varied from 5 μM to 10mM. (g) Photodiode signal response for the detection of cholesterol in buﬀer with concentrations varied
from 50 μM to 870 µM. (h) Photodiode signal response for the detection of cholesterol in diluted serum, with the concentrations varied from 100 µM to 870 µM.
Photodiode signals are given in arbitrary units (a. u.) since the oﬀset in the initial value for each measurement has been manually removed for ease of comparison in
the graphs, hence data values are not absolute. The numerical variation in signal is measured in millivolts (mV) in every case.
S.B. Patil et al. Biosensors and Bioelectronics 122 (2018) 88–94
92
order to use the system quantitatively, variation in measured activity
(transduced into biosensor response) must be a function of the meta-
bolite-substrate concentration and thus the metabolite-substrate needs
to be within a linear operable range, near or below the Michaelis
constant (Km) of the metabolite-speciﬁc enzyme. This property of the
enzyme ultimately dictates the linear dynamic range of the biosensor
(Chica et al., 2005). The biosensor response was found to be metabolite
concentration-dependent, showing a typical Michaelis-Menten kinetics
with a distinct dynamic range, indicated by the dashed line, for the
quantiﬁcation of each metabolite in the diluted serum (Fig. 4a-c and
Figs. S4c-d). The CHOD employed here exhibited a Km of 0.37mM in
buﬀer and 0.26mM in the presence of diluted serum (Fig. 4a); thus the
choline biosensor operates well below substrate saturation levels in the
linear dynamic range up to 100 µM of choline. The XOD used here
showed a Km of 0.24mM and 0.18mM in buﬀer and diluted serum,
respectively (Fig. 4b). The xanthine biosensor too, therefore operates
well below substrate saturation in the linear dynamic range of xanthine
up to 200 µM. The concentration of sarcosine in urine of normal human
subjects is approximately 0.02 µM which has been reported to increase
up to 5 μM in the patients with prostate cancer (Cernei et al., 2013). The
SOX used here showed a Km in buﬀer of 3mM and in diluted urine of
7.3 mM (Fig. 4c); hence the sarcosine biosensor also operates well
below substrate saturation in the linear dynamic range up to 2mM
sarcosine with the lowest detectable concentration of 1.25 μM, thus
reaching detectable levels in patients.
To validate our CMOS device, we investigated the detection of two
commonly used metabolites, cholesterol and glucose, which are mar-
kers for the risk of cardiovascular disease and diabetes respectively.
Similar peroxidase coupled colour reactions were adopted and mon-
itored in real time using photodiode sensors (Fig. S4a-d). The accuracy
of the values obtained using the CMOS-based device was validated by
comparison of unknown serum values measured against UK NHS la-
boratory certiﬁed measurements for glucose and cholesterol on an
Abbott ARCHITECT clinical chemistry analysis platform (Abbott, Illi-
nois, USA). These assays were carried out, using enzymatic methods, for
the same serum sample. The bar chart (Fig. 5) depicts the measured
values for glucose and cholesterol using the two independent quanti-
ﬁcation methodologies (metabolites measured in the ARCHITECT
system and CMOS-based device). There was no statistically signiﬁcant
diﬀerence between the two groups of measurements as indicated by the
Fig. 4. On-chip kinetic analysis using photodiode sensor array. (a) Initial
rates for choline in buﬀer (red) and in diluted serum (green), with concentra-
tions varied from 25 μM to 500 µM. (b) Initial rates for xanthine in buﬀer (red)
and in diluted serum (green), with concentrations varied from 0.1mM to
1.6 mM and 0.1–0.8 mM, respectively. (c) Initial rates for sarcosine in buﬀer
(red) and in diluted urine (green), with concentrations varied from 1.25 μM to
10mM and 5 μM to 10mM, respectively. The dashed lines in the kinetics curves
depict the linear dynamic range for on-chip assay in the diluted serum. The data
shown are the mean of independent experiments (n=4) and the error bars
show the standard error of the mean (SEM).
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Fig. 5. The validation of handheld CMOS device. The plot depicts the
measured values of glucose and cholesterol using two independent quantiﬁca-
tion methodologies. The same human serum sample was tested at NHS on an
Abbott ARCHITECT clinical chemistry analyser (n=8) and by our handheld
CMOS-based device (n=4). The statistical diﬀerence between the two groups
of determined values was evaluated using a Student unpaired t-test. There is no
statistically signiﬁcant diﬀerence between the two groups of measurements as
indicated by the p values (> 0.05).
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p values (> 0.05 using Student unpaired t-test). These results indicate
that our CMOS-based device can reliably quantify these metabolites in
clinical samples. In addition, this technology oﬀers the advantage of
performing multiplexed detection of diﬀerent analytes covering meta-
bolomic and immunological biomarkers (Nagy et al., 2018).
Having demonstrated each of the target assays, and obtained ver-
iﬁcation that glucose and cholesterol levels were well matched to
available NHS assays, we then showed that we could assay four meta-
bolites simultaneously using this handheld platform. A movie of real
time outputs is shown in the Supplementary Information (Fig. S5;
Movie Clip 1) demonstrating successful detection of all four metabo-
lites together.
This ability of a CMOS based platform to detect and quantify cho-
line, xanthine, sarcosine and cholesterol simultaneously, with an assay
time of just 2 min, demonstrates new potential for a rapid POC platform
for diagnosing multiple diseases using metabolite proﬁling. The suc-
cessful simultaneous quantiﬁcation of multiple metabolites also points
to the feasibility of scaling this technology to measure a wider range of
metabolites, capable of diagnosing many diseases as their metabolic
perturbations become evident.
4. Conclusions
We have developed a handheld device based on CMOS technology
capable of quantifying multiple metabolites choline, xanthine, sarco-
sine, and cholesterol simultaneously using speciﬁc enzymes. These
metabolites, proposed as potential biomarkers for acute ischaemia (for
heart or brain), acute renal failure and prostate cancer, were detected in
less than 2min oﬀering the potential to use this handheld device in
clinical and non-clinical settings. Furthermore, the biosensor perfor-
mance was validated for measurement accuracy using glucose and
cholesterol by comparison to NHS certiﬁed tests for the same metabo-
lites. All of these measurements are conducted using an autonomous
handheld device based on chip-based technology integrated into a
mobile handheld unit. Having demonstrated the ability to measure
multiple metabolites simultaneously we are now in a position to scale
up the numbers of enzymes applied to the chip surface with a long-term
aim of generating arrays suitable for diagnosing any disease for which
metabolic perturbations are known. The technology has general ap-
plicability in primary and personal care settings, alleviating the burden
on healthcare provision world-wide. We expect future versions of the
technology to embed microﬂuidic sample handling and enzyme im-
mobilisation (Sunayama and Takeuchi, 2014) to remove the need for
oﬀ-chip sample preparation.
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